(Q34235325)

31 July 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review (English)

1 reference

31 July 2017

1 reference

1 reference

Jhee SS

1

1 reference

31 July 2017

Shiovitz T

series ordinal

2

1 reference

31 July 2017

Crawford AW

series ordinal

3

1 reference

31 July 2017

Cutler NR

series ordinal

4

1 reference

31 July 2017

publication date

1 January 2001

1 reference

Clinical Pharmacokinetics

31 July 2017

published in

1 reference

31 July 2017

volume

40

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

189-205

1 reference

The safety of concomitant use of sumatriptan and antidepressant treatments

31 July 2017

cites work

1 reference

12 December 2020

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

1 reference

12 December 2020

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

1 reference

12 December 2020

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group

1 reference

12 December 2020

A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine

1 reference

12 December 2020

Effect of subcutaneous naratriptan on forearm blood flow.

1 reference

12 December 2020

Side effects of ergotamine

1 reference

12 December 2020

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

1 reference

12 December 2020

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

1 reference

12 December 2020

Distribution and excretion of sumatriptan in human milk

1 reference

12 December 2020

The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.

1 reference

12 December 2020

Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients

1 reference

12 December 2020

Pharmacokinetics and food interaction of MK-462 in healthy males

1 reference

12 December 2020

The clinical pharmacokinetics of zolmitriptan.

1 reference

12 December 2020

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

1 reference

12 December 2020

Eletriptan and coronary artery

1 reference

12 December 2020

Naratriptan: biological profile in animal models relevant to migraine

1 reference

12 December 2020

Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience

1 reference

12 December 2020

Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans

1 reference

12 December 2020

The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers

1 reference

12 December 2020

The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers

1 reference

12 December 2020

Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group

1 reference

12 December 2020

Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries

1 reference

12 December 2020

Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison

1 reference

12 December 2020

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

1 reference

12 December 2020

Migraine: a comprehensive review of new treatment options

1 reference

12 December 2020

Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence

1 reference

12 December 2020

Pharmacokinetics of rizatriptan tablets during and between migraine attacks

1 reference

12 December 2020

No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.

1 reference

12 December 2020

Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.

1 reference

12 December 2020

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

1 reference

12 December 2020

Lack of pharmacokinetic interaction between sumatriptan and naproxen

1 reference

12 December 2020

Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan

1 reference

12 December 2020

Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90)

1 reference

12 December 2020

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

1 reference

12 December 2020

Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group

1 reference

12 December 2020

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

1 reference

12 December 2020

Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

1 reference

12 December 2020

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

1 reference

12 December 2020

Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans

1 reference

12 December 2020

Single dose pharmacokinetics of sumatriptan in healthy volunteers

1 reference

12 December 2020

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

1 reference

12 December 2020

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

1 reference

12 December 2020

Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate

1 reference

12 December 2020

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

1 reference

12 December 2020

Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

1 reference

12 December 2020

Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development

1 reference

12 December 2020

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers

1 reference

12 December 2020

Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses

1 reference

12 December 2020

Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.

1 reference

12 December 2020

A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine

1 reference

12 December 2020

Cephalic hyperemia during migraine headaches. A prospective study

1 reference

12 December 2020

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

12 December 2020

How does sumatriptan perform in clinical practice?

1 reference

12 December 2020

Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine

1 reference

12 December 2020

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group

1 reference

12 December 2020

Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver

1 reference

12 December 2020

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

12 December 2020

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

1 reference

12 December 2020

Oral sumatriptan in acute migraine

1 reference

12 December 2020

Naratriptan: an alternative for migraine

1 reference

12 December 2020

Mode of action of the anti-migraine drug sumatriptan

1 reference

12 December 2020

Lack of an interaction between propranolol and sumatriptan

1 reference

12 December 2020

Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan

1 reference

12 December 2020

Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?

1 reference

12 December 2020

Permeation of sumatriptan through human vaginal and buccal mucosa

1 reference

12 December 2020

Sumatriptan clinical pharmacokinetics

1 reference

12 December 2020

Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group.

1 reference

12 December 2020

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

1 reference

12 December 2020

Serotonin (5-HT) and migraine

1 reference

12 December 2020

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors

1 reference

12 December 2020

Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group

1 reference

12 December 2020

Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study

1 reference

12 December 2020

Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers

1 reference

12 December 2020

Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies

1 reference

12 December 2020

Clinical and experimental effects of sumatriptan in humans

1 reference

12 December 2020

The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache

1 reference

12 December 2020

The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers

1 reference

12 December 2020

Sumatriptan contraindications and the serotonin syndrome.

1 reference

12 December 2020

Headache recurrence after subcutaneous sumatriptan and early treatment

1 reference

12 December 2020

10.2165/00003088-200140030-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1041373421

0 references

1 reference